Varying approaches: granting SPCs in Europe

Supplementary protection certificates (SPCs) are a hugely important intellectual property right for the pharmaceutical industry as they can extend patent protection for a particular pharmaceutical product for up to five additional years.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

23 July 2026 Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.

Pharma

Exelixis opens two-front patent dispute over Cabometyx copies

9 July 2026 Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.

Pharma

Influential Women in IP 2026: Who made the list?

7 July 2026 Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.

More features

Where Big Pharma is betting big in the M&A boom

Boston Scientific overturns $42m patent verdict on appeal

Buying the brains: Why is Big Pharma shopping for innovation?

FisherBroyles and Hong Kong affiliate draft in senior partners

‘Engagement and collaboration’: New IP Federation president builds on strong foundations

Trump slaps 100% tariff on generic drugs in US manufacturing push

Pharmascience v Janssen: Canada court updates methods of medical treatment protection

UK Prime Minister axes science ministry in govt shakeup

Varying approaches: granting SPCs in Europe

More on this story

Editor's picks

Editor's picks

More features